An MCAS test is a set of measurements led by serum tryptase: one drawn at baseline and one within hours of a flare, where a rise above 120% of baseline plus 2 ng/mL supports the diagnosis (consensus criteria). Tryptase peaks 1 to 2 hours after a reaction, so a draw on a quiet day can read normal (Schwartz et al., 1989).
Key takeaways
- The core MCAS testing workup is serum tryptase (baseline and during a reaction) and 24-hour urine for mediators like N-methylhistamine and prostaglandin metabolites.
- Diagnosis is clinical. There is no single validated diagnostic blood biomarker for MCAS, and the mediator tests are timing-sensitive and often normal.
- Tryptase and histamine are the mast cell mediators. A broad inflammation panel does not measure those; it measures cytokines and chemokines that sit around the inflammatory response.
- That broader signaling is context, not a replacement for mediator testing and not a diagnosis.
- Because MCAS symptoms overlap heavily with long COVID, ME/CFS, and dysautonomia, many people benefit from an objective picture to bring to their own doctor.
What does the standard MCAS test measure?
The consensus workup for a suspected mast cell activation syndrome test has three parts. First, a serum tryptase level at baseline, when you are not reacting. Tryptase is an enzyme stored in mast cells, so a resting level sets your personal reference. Second, a tryptase drawn during a flare, ideally within a few hours of symptom onset, to look for a documented rise above baseline. Third, 24-hour urine collections for mediator metabolites, commonly N-methylhistamine (a histamine breakdown product), prostaglandin D2 metabolites, and sometimes leukotriene E4.
The logic is direct. If mast cells are activating abnormally, the chemicals they release, or the products those chemicals break down into, should be detectable. When a flare-time tryptase rises by a defined amount over baseline, that is treated as objective evidence of mast cell activation. It is a real, useful test when the timing works.
Why does the standard MCAS test so often come back normal?
Timing is the hard part. Tryptase peaks within roughly one to two hours of a reaction and falls back within hours, so a level drawn the next day, or during a quiet week, can look completely normal even in someone who reacts often. Urine collections face the same problem: you are trying to capture a 24-hour window that happens to contain a flare. Miss the window and the result is unremarkable. Many people cycle through several draws, spend real money, and still end up told their results are "fine" while their symptoms are anything but.
This is where the familiar frustration sets in. A normal tryptase does not mean nothing is happening. It often means the test did not catch the moment. That gap is one reason MCAS remains a clinical diagnosis built on the pattern of symptoms across body systems, response to mediator-targeting treatment, and objective mediator evidence when it can be captured. If your MCAS symptoms sound like other post-viral conditions, our piece on why MCAS symptoms overlap with long COVID and ME/CFS covers that ground.
What does a broad inflammation profile add, and what can it not do?
A broad panel reads tryptase beside the type-2 and alarmin cytokines (IL-4, IL-5, IL-13, IL-33, TSLP) against a healthy reference at the time of the draw. It does not replace an event tryptase timed to a flare, and it does not measure histamine or prostaglandins; those remain the job of the standard workup above. A wide cytokine and chemokine panel also reads the inflammatory signaling network that surrounds a mast cell response: proteins like IL-6, TNF, IL-1 beta, interferon-inducible chemokines such as CXCL10 (IP-10), and monocyte chemoattractants like CCL2 (MCP-1). Mast cells both release some of these and respond to them, so this is the wider conversation the mediator tests do not capture.
Two honest limits. First, this is context, not a replacement: it does not substitute for a tryptase or a urinary mediator test, and it does not confirm or rule out MCAS. Second, it is not a diagnosis of anything. It is measurement and benchmarking for research and informational use, to review with your own doctor. To understand how mast cells relate to these signals, see our explainer on mast cells and cytokines.
How can objective inflammation data help when your MCAS test is normal?
When the standard mediator tests come back normal but you are still reacting, you are left with a story and no numbers. A broad panel gives you numbers of a different kind. It measures a 1,000+ marker inflammation proteomics panel from a small at-home microsample, benchmarks each cytokine and chemokine against a healthy reference range so "normal" becomes "in range or not," and lets you retest over time to see what changes.
You can see what Mune Mirror™* measures and bring the results to your own doctor. It is not a substitute for the tryptase-and-urine workup, and it is not a substitute for medical care. It is a way to hold objective inflammatory-signaling data alongside a diagnosis that, today, has no single blood test to confirm it.
Frequently asked questions
Is there a single blood test that diagnoses MCAS?
No. There is no single validated diagnostic blood biomarker for MCAS. Diagnosis is clinical and relies on the pattern of symptoms across organ systems, objective mediator evidence such as a flare-time tryptase rise when it can be captured, and response to mediator-targeting treatment. Mediator tests support the picture but do not stand alone.
Why was my tryptase normal even though I clearly react?
Tryptase rises within one to two hours of a reaction and falls back quickly, so a level drawn outside that window often reads normal. A normal result does not rule out mast cell activation; it frequently means the draw missed the flare. Baseline and flare-time levels together are more informative than a single random test.
Does Mune test for tryptase or histamine?
No. Mune does not measure tryptase, histamine, prostaglandins, or DAO, which are the classic mast cell and histamine markers. Mune measures a broad panel of inflammatory cytokines and chemokines, such as IL-6, TNF, and CXCL10, as added signaling context. That is informational and for research use, not a diagnosis and not a replacement for the standard MCAS workup.
Can an inflammation panel replace the standard MCAS workup?
No. A cytokine and chemokine panel is context that sits alongside the standard workup, not a replacement for it. Serum tryptase and urinary mediator testing remain the mediator-specific tests. Any inflammation results should be reviewed with your own doctor together with the standard evaluation.
Where Mune Mirror™ fits
Mune Mirror™ measures more than 1,000 immune and inflammation proteins from an at-home sample, benchmarks each against a healthy reference and repeats the measurement over time, so you have a measured record to bring to your own doctor. It does not diagnose any condition.
Unwellness testing is blood testing for people whose standard labs come back normal but who still feel unwell: the people medicine has no answers for yet. It measures highly selected immune and inflammatory proteins that routine panels do not, so persistent symptoms can be tracked and made visible against a healthy reference. Mune Mirror™ is investigational and for research and informational use. It does not diagnose, treat, cure or prevent any disease.
Mune Mirror™ is currently in development, and the performance characteristics of this test have not yet been established. It is investigational. It does not diagnose, detect, screen for, treat, cure or prevent any disease. Results are for research and informational purposes, to discuss with your own doctor.